A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)
The goal of this clinical research study is to learn if KTE-C19 can help to control relapsed/refractory MCL when given after a 3-day course of chemotherapy. The safety of the drug will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 12/18/2015
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: